Seventeen-year Millennium Pharmaceuticals veteran Anna Protopapas began her first day as president and CEO of Mersana Therapeutics on 2 March with an announcement that the antibody-drug conjugate (ADC) specialist closed a $35m Series B venture capital round.
The money gives Cambridge, Massachusetts-based Mersana enough cash, on top of fees from ongoing ADC co-development partnerships, to initiate trials...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

